10 completed, 2 withdrawn. 11 Phase 2, 2 Phase 1.
By phase and status
Follow Tesofensine: new trials by email Literature Review of Tesofensine trials Research Report on Tesofensine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome Placebo, Tesomet - Prader-Willi Syndrome Phase 2 Withdrawn Saniona 2021-12-28 2022-12-13 Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO) Placebo, Tesomet - Hypothalamic Obesity Phase 2 Withdrawn Saniona 2021-11-11 2022-12-13 48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO) Tesofensine/Metoprolol, Placebo - Hypothalamic Injury-induced Obesity (HIO) Phase 2 Completed Saniona 21 2019-02-25 2024-02-13 Study to Investigate the Pharmacokinetic Profile Tesomet "High dose" in fasted condition, Tesomet "Low dose" in fasted condition, Comperator 1 mg tesofensine, 25 mg commercial IR metoprolol, 75 mg commercial ER metoprolol, fasted condition. - Healthy Male Subjects Phase 1 Completed Saniona 60 2017-12-18 2020-05-14 Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS) Tesofensine/Metoprolol, Placebos - Confirmed Genetic Diagnosis of Prader-Willi Syndrome Phase 2 Completed Saniona 18 2017-03-30 2024-02-26 Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus Tesofensine/Metoprolol, Placebo - Type 2 Diabetes Mellitus Phase 2 Completed Saniona 60 2016-04-01 2020-05-14 Evaluation of Long Term Safety of Tesofensine in Patients With Obesity Tesofensine - Obesity Phase 2 Completed NeuroSearch A/S 140 2007-05-01 2011-07-04 Effect of Tesofensine on Energy Balance in Humans. Tesofensine - Obesity Phase 1 / Phase 2 Completed NeuroSearch A/S 32 2007-03-01 2008-03-05 Effect of Tesofensine on Weight Reduction in Patients With Obesity. Tesofensine - Obesity Phase 2 Completed NeuroSearch A/S 200 2006-09-01 2013-04-22 A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE) NS 2330 - Parkinson Disease Phase 2 Completed Boehringer Ingelheim 261 2003-06-01 2013-10-29 A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations 1. Tesofensine (NS 2330) - Parkinson Disease Phase 2 Completed Boehringer Ingelheim 254 2003-03-01 2013-10-29 An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type NS 2330 (Tesofensine) - Alzheimer Disease Phase 2 Completed Boehringer Ingelheim 430 2003-02-01 2013-10-29
Conditions studied Obesity (3) · Parkinson Disease (2) · Alzheimer Disease (1) · Diabetes Mellitus, Type 2 (1) · Hyperphagia (1) · Prader-Willi Syndrome (1) · Sexual Infantilism (1)
Sponsors Saniona (6) · Boehringer Ingelheim (3) · NeuroSearch A/S (3)
Countries Denmark (4) · United States (4) · Germany (3) · Canada (2) · Austria (1) · Czechia (1) · France (1) · Hungary (1) · Netherlands (1) · Spain (1) · United Kingdom (1)
Top investigators Arne V Astrup, MD (2) · Sophie Guillaume, MS (2) · Arne V Astrup, Professor, MD (1) · Jorgen Drejer, PhD (1) · Kim Krogsgaard, MD, DMSc (1) · Ulla Feldt-Rasmussen, MD, DMSc (1)
Results publications PMID 21720440 , PMID 18474731 , PMID 18950853